NewGenIvf Group (NASDAQ:NIVF) Issues Earnings Results

NewGenIvf Group (NASDAQ:NIVF) issued its quarterly earnings data on Wednesday. The company reported ($13.32) earnings per share for the quarter, FiscalAI reports. The company had revenue of $0.96 million during the quarter.

NewGenIvf Group Stock Performance

Shares of NIVF traded up $0.01 during midday trading on Wednesday, hitting $0.11. The company had a trading volume of 158,468,859 shares, compared to its average volume of 8,085,030. The company’s 50-day simple moving average is $1.22 and its 200-day simple moving average is $7.13. NewGenIvf Group has a 1 year low of $0.06 and a 1 year high of $1,539.00.

Insider Activity

In other NewGenIvf Group news, Director Kong Yiu Cheung purchased 2,500,000 shares of the firm’s stock in a transaction on Monday, July 27th. The stock was bought at an average cost of $1.00 per share, with a total value of $2,500,000.00. Following the acquisition, the director directly owned 3,722,223 shares of the company’s stock, valued at approximately $3,722,223. This represents a 204.55% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 31.80% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently weighed in on NIVF. Wall Street Zen upgraded NewGenIvf Group to a “hold” rating in a report on Saturday, July 4th. Weiss Ratings reissued a “sell (d)” rating on shares of NewGenIvf Group in a research note on Friday, July 24th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has an average rating of “Sell”.

NewGenIvf Group Company Profile

NewGenIvf Group Limited is a fertility-services company that provides assisted reproductive and related medical services. Through its NewGen IVF network, the company serves individuals and couples seeking fertility evaluation, in vitro fertilization (IVF), and other treatments designed to support conception.

Its services include fertility consultations and diagnostic testing, ovarian stimulation, egg retrieval, embryo transfer, intracytoplasmic sperm injection (ICSI), embryo and reproductive-cell freezing, and preimplantation genetic testing.